广东宏荣环境科技有限公司
广东宏荣环境科技有限公司坐落于惠州市仲恺高新开发区,是一家集研发、咨询、设计、设备制造、工程建设、系统运营以及环保管家综合服务(环评审批、验收监测、环保验收、环保排污许可证及环境突发事件应急预案、“一企一策”、清洁生产等服务)于一体的综合性环保服务企业。 公司成立于2012年,前身为惠州节能环保公司,因业务升级,为了更好的服务客户,现变更为广东宏荣环境科技有限公司。公司由十几年环保经验的资深工程师和技术人员组成的集水处理、废气(VOCs)处理、粉尘处理、噪声处理等环保设备制作、工程设计、工程安装等于一体的专业环保技术团队,能够对各种环境污染项目进行完善的分析、研究、设计、治理。
惠州低温等离子净化器 惠州高效除尘设备布袋除尘器 惠州高效水喷淋净化塔 惠州UV光触媒净化器 惠州活性炭吸附塔 惠州工业污水处理系统 惠州脱硫除尘系统 惠州RCO/CO催化燃烧系统 惠州粉尘废气处理设备 惠州车间粉尘处理 惠州工业除尘器 惠州打磨抛光粉尘设备
百度权重
百度移动
360权重
搜狗权重
站点URL: http://www.gdhrep.com · 站点编号:76661 · 加入时间:0000-00-00 00:00:00
做上本站友情链接,在您站上点击一次,即可自动秒收录并自动排在本站第一位!<a href="https://www.9sl.cn/" target="_blank">玖收录</a>
域名(www.gdhrep.com)由网友主动性提交被玖收录整理收录的,本页最后更新时间为:2023-11-28 13:31:51,玖收录仅提供www.gdhrep.com的基础信息并免费向广大游客展示,该站IP地址为,该站打开速度为,该站的百度权重为、百度手机权重为、百度收录为条、360收录为条、搜狗收录为条、谷歌收录为条、百度来访流量大约在之间、百度手机端来访流量大约在之间、www.gdhrep.com的备案号是、备案人叫、被百度收录的关键词有个、手机端关键词有个、迄今为止已经创建,其内容不代表本站赞成被显示该站点的内容或立场,相关资料: txt下载、docx下载、pdf下载、rar下载、zip下载,本页地址:https://www.9sl.cn/links/797ca540bfbad5c22d7b.html。

WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity,foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.